Publications by authors named "A V Orlova"
The transcription factors STAT3, STAT5A, and STAT5B steer hematopoiesis and immunity, but their enhanced expression and activation promote acute myeloid leukemia (AML) or natural killer/T cell lymphoma (NKCL). Current therapeutic strategies focus on blocking upstream tyrosine kinases to inhibit STAT3/5, but these kinase blockers are not selective against STAT3/5 activation and frequent resistance causes relapse, emphasizing the need for targeted drugs. We evaluated the efficacy of JPX-0700 and JPX-0750 as dual STAT3/5 binding inhibitors promoting protein degradation.
View Article and Find Full Text PDFConventional drug delivery systems often suffer from non-specific distribution and limited therapeutic efficacy, leading to significant side effects. To address these challenges, we developed magnetoelectric, cobalt ferrite@barium titanate (CFO@BTO) nanofibers (NFs), with a core-shell structure for targeted anticancer drug delivery. The electrospinning method was employed to synthesize polymeric NFs based on magnetoelectric core-shell nanostructures.
View Article and Find Full Text PDFThe effects of cytotoxic chemotherapy on tumor vasculature and oxygenation are in the focus of modern investigations because vascular structure and distribution of oxygen influence tumor behavior and treatment response. The aim of our study was to monitor changes in the vascular component of colorectal tumor xenografts induced by a clinical combination of chemotherapy drugs FOLFOX in vivo using two complementary techniques: diffuse reflectance spectroscopy (DRS) and optical coherence tomography-based microangiography (OCT-MA). These techniques revealed a slower decrease in tumor blood oxygenation in treated tumors as compared to untreated ones, faster suppression of tumor vasculature perfusion and increase in water content as a result of treatment, and decrease in total hemoglobin in untreated tumors.
View Article and Find Full Text PDFArticle Synopsis
- Clinical trials for drugs targeting HER3 have struggled due to inefficacy, despite some cancer patients having higher levels of HER3 expression.
- Novel drug delivery methods, such as affibody-based conjugates targeting HER3, are being explored to improve treatment outcomes.
- The study demonstrated that a specific drug conjugate (Z-ABD-Z-mcDM1) showed promising tumor growth inhibition and extended survival in mice with pancreatic cancer compared to other treatments.*
Article Synopsis
- * However, the complexity of OA data collection and processing can lead to inconsistent methodologies among different users and developers.
- * To address this, SKYQUANT 3D is introduced as a Python-based workflow that streamlines the analysis of 3D OA images, enabling easier batch processing, quantitative analysis, and graphical representation of results demonstrated in various preclinical and clinical tests.